Madrigal Study Finds Rezdiffra Benefits Across Genetic Risks
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) reported that its liver disease drug Rezdiffra improved measures of liver damage across patients carrying common genetic risk variants for metabolic dysfunction-associated …
Madrigal Study Finds Rezdiffra Benefits Across Genetic Risks Read More